Cointime update: Fosun Pharma said global multicenter Phase III trial data for its oral investigational drug AR1001 in early Alzheimer’s disease showed a between-group difference between the treatment arm and placebo in the overall population, but the result did not reach statistical significance. The company disclosed the topline finding without providing further efficacy detail.
Fosun Pharma: Oral Alzheimer’s Drug AR1001 Misses Statistical Significance in Phase III
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
Iran military says it struck US drone and missile facilities at Kuwait’s Ali Al Salem base
1h ago
MARA Sells 1,713.9 BTC for $121M; BOJ Signals More Rate Hikes
2h ago
BOJ’s Ueda Says Rate Hikes Should Continue to Anchor Inflation
3h ago
South Korea’s KOSPI Turns Negative After Earlier Gaining Over 3%
3h ago
Spot silver falls 2.00% intraday to $46.44/oz, lowest since Sept 29, 2025
3h ago
Spot gold falls below $3,800/oz for first time since Sept 30